Immutep Ltd (IMM) reported positive results from its preclinical study of IMP761. Based on the results of this in vivo study which confirms the immunosuppressive activity of IMP761 on the inflammation associated with an antigen-induced T cell response in non-human primate tissues, Immutep will advance IMP761 into clinical development
http://crweworld.com/article/news-provided-by-globenewswire/1007643/immutep-presents-positive-imp761-preclinical-results-at-14th-congress-of-european-crohns-and-colitis-organisation
Ann: IMP761 results presented at ECCO conference, page-8
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 31.0¢ | 32.0¢ | 30.3¢ | $884.2K | 2.836M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34624 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 250082 | 6 |
View Market Depth
| Last trade - 16.10pm 27/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
